Neurogene Inc (NASDAQ: NGNE) kicked off on Monday, up 7.26% from the previous trading day, before settling in for the closing price of $29.89. Over the past 52 weeks, NGNE has traded in a range of $6.88-$74.49.
A company in the Healthcare sector has dropped its sales by -10.74% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -10.28%. With a float of $12.14 million, this company’s outstanding shares have now reached $14.27 million.
Neurogene Inc (NGNE) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Neurogene Inc is 14.93%, while institutional ownership is 96.21%. The most recent insider transaction that took place on May 14 ’25, was worth 103,003. In this transaction Chief Scientific Officer of this company sold 6,797 shares at a rate of $15.15, taking the stock ownership to the 20,794 shares. Before that another transaction happened on May 14 ’25, when Company’s Officer proposed sale 6,797 for $15.51, making the entire transaction worth $105,421.
Neurogene Inc (NGNE) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.19 earnings per share (EPS), higher than consensus estimate (set at -1.22) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -23.39% during the next five years compared to -10.74% drop over the previous five years of trading.
Neurogene Inc (NASDAQ: NGNE) Trading Performance Indicators
Take a look at Neurogene Inc’s (NGNE) current performance indicators. Last quarter, stock had a quick ratio of 18.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.63, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -5.91 in one year’s time.
Technical Analysis of Neurogene Inc (NGNE)
Let’s dig in a bit further. During the last 5-days, its volume was 0.26 million. That was better than the volume of 0.22 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 23.96%.
During the past 100 days, Neurogene Inc’s (NGNE) raw stochastic average was set at 76.98%, which indicates a significant increase from 63.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.73 in the past 14 days, which was higher than the 1.84 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.49, while its 200-day Moving Average is $18.65. However, in the short run, Neurogene Inc’s stock first resistance to watch stands at $33.57. Second resistance stands at $35.07. The third major resistance level sits at $37.15. If the price goes on to break the first support level at $29.99, it is likely to go to the next support level at $27.91. Assuming the price breaks the second support level, the third support level stands at $26.41.
Neurogene Inc (NASDAQ: NGNE) Key Stats
The company with the Market Capitalisation of 457.56 million has total of 14,272K Shares Outstanding. Its annual sales at the moment are 930 K in contrast with the sum of -75,140 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -22,020 K.
